AVBP NASDAQ
ArriVent BioPharma, Inc.
1W: -18.3%
1M: -47.4%
3M: -48.7%
YTD: -26.0%
1Y: -17.2%
$15.40
+0.04 (+0.26%)
Weekly Expected Move ±26.1%
$10
$16
$21
$26
$32
Credit Risk of going bust: lower than 76% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), ArriVent BioPharma, Inc. would be worth roughly what it owes.
Total debt $351K against a stock market value of $759.3M.
Distance to default 8.74 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $176K (short-term plus half of long-term), stock volatility 91.5%; Altman Z'' 13.01. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), ArriVent BioPharma, Inc. would be worth roughly what it owes.
Total debt $351K against a stock market value of $759.3M.
Distance to default 8.74 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $176K (short-term plus half of long-term), stock volatility 91.5%; Altman Z'' 13.01. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
3 relationships3
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2024-06-05
Earliest Filing
2025-01-22
Latest Filing
partner: 3
Counterparties (Filed by AVBP)
3 relationshipsCompanies named in AVBP's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Lepu Biopharma Co., Ltd. | — | partner | Exclusive license agreement for MRG007 development and commercialization outside Greater China | 2025-01-22 | View |
| Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | — | partner | Entered into a Research and Collaboration Agreement for discovering, developing, and commercializing novel antibody drug | 2024-06-05 | View |
| Alphamab Oncology | — | partner | Parent company of Jiangsu Alphamab Biopharmaceuticals Co., Ltd., a party to the collaboration agreement. | 2024-06-05 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-26 | Regulation FD; Other Events; Exhibits | View | |
| 2026-10-19 | Regulation FD; Exhibits | View | |
| 2026-10-13 | Regulation FD; Other Events; Exhibits | View | |
| 2026-10-06 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-12 | Material Agreement; Earnings Release; Exhibits | Agreement | View |
| 2026-06-22 | Shareholder Vote | View | |
| 2026-05-11 | Earnings Release; Exhibits | View | |
| 2026-05-11 | Other Events; Exhibits | View | |
| 2026-03-17 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2026-03-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-09 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-21 | Other Events; Financial Statements and Exhibits | View | |
| 2025-07-02 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-06-23 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-06-20 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-28 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-03-13 | Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR